These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 25163706

  • 1. The New Zealand Psychoactive Substances Act (PSA): a policy breakthrough or just a symbolic act?
    Bretteville-Jensen AL.
    Addiction; 2014 Oct; 109(10):1590-1. PubMed ID: 25163706
    [No Abstract] [Full Text] [Related]

  • 2. Response to commentaries.
    Wilkins C.
    Addiction; 2014 Oct; 109(10):1593-4. PubMed ID: 25163708
    [No Abstract] [Full Text] [Related]

  • 3. Prohibition is a key driver of the new psychoactive substances (NPS) phenomenon.
    Rolles S, Kushlick D.
    Addiction; 2014 Oct; 109(10):1589-90. PubMed ID: 25163705
    [No Abstract] [Full Text] [Related]

  • 4. New psychoactive substances: issues about the new approach from New Zealand government.
    von Diemen L.
    Addiction; 2014 Oct; 109(10):1588-9. PubMed ID: 25163704
    [No Abstract] [Full Text] [Related]

  • 5. Deconstructing Designer Drugs.
    Sellers EM.
    Clin Pharmacol Ther; 2017 Feb; 101(2):167-169. PubMed ID: 27564430
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A critical analysis of the implementation of a legal regulated market for new psychoactive substances ("legal highs") in New Zealand.
    Rychert M, Wilkins C.
    Int J Drug Policy; 2018 May; 55():88-94. PubMed ID: 29524738
    [Abstract] [Full Text] [Related]

  • 10. Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory.
    Rychert M, Wilkins C.
    Addiction; 2018 Nov; 113(11):2132-2139. PubMed ID: 29744945
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Legal high industry business and lobbying strategies under a legal market for new psychoactive substances (NPS, 'legal highs') in New Zealand.
    Rychert M, Wilkins C.
    Int J Drug Policy; 2016 Nov; 37():90-97. PubMed ID: 27639994
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Issues with monitoring the safety of psychoactive products under a legal regulated market for new psychoactive substances ('legal highs') in New Zealand.
    Rychert M, Wilkins C, Witten K.
    Drug Alcohol Rev; 2017 Sep; 36(5):589-596. PubMed ID: 28229493
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. To prohibit or regulate psychoactive substances: has New Zealand got the right approach?
    Rizwan SB, Vernall AJ.
    BMJ; 2017 Mar 17; 356():j1195. PubMed ID: 28314708
    [No Abstract] [Full Text] [Related]

  • 20. Are government-approved products containing new psychoactive substances perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand.
    Rychert M, Wilkins C, Parker K, Witten K.
    Drug Alcohol Rev; 2018 Mar 17; 37(3):406-413. PubMed ID: 29285812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.